ConductScience.org, home

Library / Trials

Efficacy and Safety of Polisorb® MP in the Complex Therapy of Patients With Atopic Dermatitis

NCT07929181, Phase 3, Completed, Polisorb Joint Stock Company

Trial 10

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

FieldValueSource
TitleEfficacy and Safety of Polisorb® MP in the Complex Therapy of Patients With Atopic DermatitisClinicalTrials.gov
NCT numberNCT07929181ClinicalTrials.gov
StatusCompletedClinicalTrials.gov
PhasesPhase 3ClinicalTrials.gov
Enrollment161 participants, actualClinicalTrials.gov
Lead sponsorPolisorb Joint Stock CompanyClinicalTrials.gov
ConditionsAtopic DermatitisClinicalTrials.gov
InterventionsColloidal Silicon Dioxide, Basic Therapy for Atopic DermatitisClinicalTrials.gov
First posted2026-11-10ClinicalTrials.gov
Last updated2026-11-10ClinicalTrials.gov

Registered outcomes 1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescriptionSource
PrimaryChange in Scoring Atopic Dermatitis (SCORAD) Index from Baseline to Day 14Baseline to Day 14
Change in the Scoring Atopic Dermatitis (SCORAD) Index from baseline to Day 14. The SCORAD Index ranges from 0 to 103, with higher scores indicating more severe atopic dermatitis and lower scores indicating less severe disease. Changes were evaluated in patients receiving basic therapy alone and in patients receiving basic therapy in combination with Polisorb® MP.
ClinicalTrials.gov

Outcomes 0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured asSource

Results by group 0

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnitsSource

Participant flow 0

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits countedSource

Adverse events 0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEventsSource

Adverse event totals 0

The totals the trial posted for each group.

TotalGroupAffectedAt riskSource

Papers 0

The papers the trial lists on ClinicalTrials.gov.

PMIDListed asSource

Grants 0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

ProjectTitlePrincipal investigatorsOrganizationFunderFiscal yearsSource

Trial comparisons 0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource

Tests 0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

TestNamed asSource

Source 5

FieldValueSource
Releasetrials-2026-11-12-0.4.0ClinicalTrials.gov
Release manifest SHA-2560f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4ClinicalTrials.gov
Registry capture2026-11-12ClinicalTrials.gov
Results copy, AACT2026-03-23ClinicalTrials.gov
NIH clinical studies file2026-11-13ClinicalTrials.gov

The same record as JSON

Release trials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)